Q-omics provides the consensus-scored CACNA1E profile across patient tissues and cancer cell-line models. CACNA1E expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CACNA1E is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, CACNA1E RNA expression shows 11,830 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, KICH, and TGCT as cancer lineages where CACNA1E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CACNA1E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CACNA1E survival associations across molecular data types. CACNA1E RNA expression shows survival associations in the most cancer types (23), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CACNA1E RNA expression–survival associations across cancer types. High CACNA1E expression shows unfavorable associations in ACC, UVM, KICH and LIHC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CACNA1E RNA expression.
This table summarizes CACNA1E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for CACNA1E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CACNA1E shows lower tumor expression in KICH and higher tumor expression in LUAD, HNSC, KIRC, BRCA and LIHC. The KICH box plot shows higher CACNA1E RNA expression in normal versus tumor tissue (log2 FC = −0.461, t-test p < 0.001).
This table shows molecular features associated with CACNA1E in patient tissues and cancer cell lines. In patient samples, CACNA1E shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CACNA1E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LUNG_SCLC.
